$27.03+0.07 (+0.24%)
News25/Ratings6
Price$27.03+0.59 (+2.23%)
01:30 PM07:45 PM
News · 26 weeks43-40%
2025-11-022026-04-26
Mix3190d
- Insider16(52%)
- Other7(23%)
- SEC Filings7(23%)
- Leadership1(3%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Shafer Christina3 - Neurogene Inc. (0001404644) (Issuer)
- SECNeurogene Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of DirectorsMs. Shafer, a proven commercial leader in rare neurological diseases, will lead Neurogene's commercial strategy and launch readiness for NGN-401 gene therapy for Rett syndrome Ms. Mikail, President and CFO of Neurogene, adds strategic and operational leadership to the Board as Company advances key priorities Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, J.D., to its Board of Directors. Ms. Shafer brings more than 20 years of industry experience buil
- SECSEC Form DEF 14A filed by Neurogene Inc.DEF 14A - Neurogene Inc. (0001404644) (Filer)
- SECSEC Form DEFA14A filed by Neurogene Inc.DEFA14A - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 69,140 shares of the Company's common stock to four new employees (the "Inducement Grants") on April 6, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Lis
- INSIDERSEC Form 4 filed by Cvijic Christine Mikail4 - Neurogene Inc. (0001404644) (Issuer)
- INSIDERSEC Form 4 filed by Jordan Julie4 - Neurogene Inc. (0001404644) (Issuer)
- INSIDERSEC Form 4 filed by Mcminn Rachel4 - Neurogene Inc. (0001404644) (Issuer)
- SECSEC Form S-8 filed by Neurogene Inc.S-8 - Neurogene Inc. (0001404644) (Filer)
- SECSEC Form 10-K filed by Neurogene Inc.10-K - Neurogene Inc. (0001404644) (Filer)
- SECNeurogene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates100% of participants enrolled in Embolden™ registrational trial and >50% of participants dosed; on track to complete dosing in second quarter of 2026 NGN-401 has been generally well-tolerated in Phase 1/2 trial and Embolden, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026 FDA Breakthrough Therapy designation granted to NGN-401 based on positive interim safety and efficacy data from Phase 1/2 trial PPQ campaign planned to begin mid‑2026, supporting BLA readiness Strong cash position provides runway through first quarter of 2028 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to pat
- INSIDERChief Scientific Officer Cobb Stuart sold $141,446 worth of shares (6,797 units at $20.81), decreasing direct ownership by 18% to 30,497 units (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- INSIDERPresident and CFO Cvijic Christine Mikail sold $84,176 worth of shares (4,045 units at $20.81) (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- PRNeurogene to Participate in Stifel 2026 Virtual CNS ForumNeurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the Stifel 2026 Virtual CNS Forum. Format: Management will participate in a fireside chat Date: Wednesday, March 18 at 9:00 a.m. ET A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene's website under events, where a replay of the event will also be available for a limited time. About Neurogene Neurogene (NASDAQ:NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medic
- INSIDERPresident and CFO Cvijic Christine Mikail sold $120,526 worth of shares (4,800 units at $25.11) (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- PRNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 32,450 shares of the Company's common stock to four new employees (the "Inducement Grants") on March 2, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Lis
- SECNeurogene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett SyndromeBreakthrough Therapy designation granted based on interim NGN-401 Phase 1/2 data demonstrating clinically meaningful, durable and multidomain functional improvements On track to complete dosing in Embolden™ registrational trial of NGN-401 in second quarter of 2026 Plans to present additional interim Phase 1/2 clinical data in mid-2026 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NGN-401, an investigational gene therapy in late-stage clinical developmen
- INSIDERChief Scientific Officer Cobb Stuart was granted 16,500 shares, increasing direct ownership by 79% to 37,294 units (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- INSIDERChief Medical Officer Jordan Julie was granted 4,900 shares, increasing direct ownership by 58% to 13,300 units (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- INSIDERPresident and CFO Cvijic Christine Mikail was granted 22,000 shares, increasing direct ownership by 24% to 114,643 units (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- INSIDERChief Executive Officer Mcminn Rachel was granted 25,900 shares, increasing direct ownership by 2% to 1,347,659 units (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- INSIDERSEC Form 4 filed by Director Palekar Rohan4 - Neurogene Inc. (0001404644) (Issuer)